
Hologic (HOLX) Stock Forecast & Price Target
Hologic (HOLX) Analyst Ratings
Bulls say
Hologic is positioned for a strong financial outlook, primarily driven by anticipated organic revenue growth of 5-7% due to robust procedure volume growth, new product launches, and strategic acquisitions in its Diagnostics and Breast Health segments. The company’s bull case scenario suggests further revenue acceleration into the high-single digits (7-9%), supported by improved operating margins and a strong balance sheet with limited leverage. Additionally, Hologic's emphasis on margin expansion and operational efficiencies indicates a projection of 8-12% earnings growth, highlighting the firm's overall positive trajectory in its core healthcare markets.
Bears say
The financial outlook for Hologic is adversely impacted by anticipated revenue growth slowing to the low-single digits (1-4%), primarily due to weakness in its Diagnostics and Breast Health segments. Despite recent mergers and acquisitions aimed at expanding its asset base, the company has struggled to re-accelerate its top-line growth post-COVID, compounded by risks such as a weak global economy and increased competition in key markets. Consequently, Hologic's operating margins are expected to remain capped in the low-30s, limiting the potential for significant earnings per share growth.
This aggregate rating is based on analysts' research of Hologic and is not a guaranteed prediction by Public.com or investment advice.
Hologic (HOLX) Analyst Forecast & Price Prediction
Start investing in Hologic (HOLX)
Order type
Buy in
Order amount
Est. shares
0 shares